Definitive Healthcare (NASDAQ:DH) Updates Q2 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.030-0.040 for the period, compared to the consensus earnings per share estimate of 0.030. The company issued revenue guidance of $55.0 million-$56.0 million, compared to the consensus revenue estimate of $55.7 million. Definitive Healthcare also updated its FY 2026 guidance to 0.160-0.19 EPS.

Definitive Healthcare Stock Performance

Shares of NASDAQ DH opened at $0.95 on Friday. The business has a fifty day simple moving average of $1.09 and a 200 day simple moving average of $1.97. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $100.47 million, a price-to-earnings ratio of -0.59, a PEG ratio of 80.59 and a beta of 1.34. Definitive Healthcare has a one year low of $0.89 and a one year high of $4.70.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Definitive Healthcare had a positive return on equity of 3.52% and a negative net margin of 76.04%.The business had revenue of $55.93 million during the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Sell-side analysts expect that Definitive Healthcare will post 0.01 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on DH shares. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Stephens lowered their price target on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Friday, February 27th. Robert W. Baird set a $1.10 price target on Definitive Healthcare in a research report on Friday. Canaccord Genuity Group lowered their price target on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a research report on Friday, February 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $2.86.

More Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Definitive Healthcare reported Q1 2026 EPS of $0.06, ahead of the $0.03 consensus estimate, and revenue of $55.93 million, above expectations. Article Title
• Positive Sentiment: The company’s FY 2026 guidance calls for EPS of $0.16 to $0.19 and revenue of $220 million to $226 million, both modestly supportive versus market expectations. Article Title
• Neutral Sentiment: Q2 guidance was also close to estimates, with EPS of $0.03 to $0.04 and revenue of $55 million to $56 million, suggesting steady near-term performance rather than a major upside surprise. Article Title
• Neutral Sentiment: Earnings-call transcripts and pre-earnings coverage indicate investors are digesting management’s commentary for signs of sustained margin improvement and demand trends. Article Title
• Negative Sentiment: Despite the earnings beat, Definitive Healthcare still posted a negative net margin of 57.52%, highlighting ongoing profitability challenges that could limit the stock’s upside. Article Title

Institutional Trading of Definitive Healthcare

Several large investors have recently made changes to their positions in DH. AQR Capital Management LLC grew its holdings in shares of Definitive Healthcare by 56.7% during the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock worth $1,706,000 after purchasing an additional 213,562 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after purchasing an additional 7,404,363 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Definitive Healthcare by 166.0% during the first quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock worth $304,000 after purchasing an additional 65,597 shares during the last quarter. Creative Planning grew its holdings in shares of Definitive Healthcare by 41.7% during the second quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after purchasing an additional 8,428 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Definitive Healthcare during the second quarter worth $4,247,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.